Myriad Genetics (MYGN) Misses Q2 EPS by 8c, Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Myriad Genetics (MYGN) PT Lowered to $19 at Jefferies
February 7, 2020 9:14 AM ESTJefferies analyst Brandon Couillard lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $19.00 (from $23.00) while maintaining a Hold rating.
The analyst commented, "We expect MYGN to open sharply lower (down >20% after-hours) after another 2Q miss, ~50% cut to '20 EPS guide & abrupt CEO... More
Myriad Genetics (MYGN) announces Mark Capone has resigned as President and CEO
February 6, 2020 4:14 PM ESTMyriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that R. Bryan Riggsbee, Chief Financial Officer, has been appointed Interim President and CEO effective immediately and will also continue to serve as Chief Financial Officer. Mark C. Capone has resigned as President and Chief Executive Officer and as a member of the Companys Board of Directors, effective immediately. Mr. Capone will remain available to the Company to assist in this transition.
As we position Myriad for its next phase of growth and... More
